Investor Relations

Investor Profile

Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting
February 13, 2019
Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor
January 3, 2019
BioAlliance Pharma provides updates on its major achievements and reports 2013 consolidated financial results
July 27, 2014
BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions
April 8, 2014
Publication of the 2013 Registration Document
April 8, 2014
BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea
April 2, 2014

Month	Total number of outstanding shares	Theoretical voting rights	Exercisable voting rights (minus treasury shares)
January 2023	111,507,130	111,507,130	111,295,166
February 2023	111,507,130	111,507,130	111,254,817
March 2023	111,507,130	111,507,130	111,250,629
May 2023	111,507,130	111,507,130	111,233,882
June 2023	154,364,273	154,364,273	154,077,113
July 2023	154,364,273	154,364,273	154,071,116
August 2023	154,364,273	154,364,273	154,106,773
September 2023	154,364,273	154,364,273	154,060,219
October 2023	154,364,273	154,364,273	154,015,159
November 2023	154,364,273	154,364,273	154,007,073
December 2023	154,364,273	154,364,273	153,996,099

Month	Total number of outstanding shares	Theoretical voting rights	Exercisable voting rights (minus treasury shares)
January 2022	91,994,935	91,994,935	91,561,536
February 2022	91,994,935	91,994,935	91,540,114
March 2022	91,994,935	91,994,935	91,546,007
April 2022	111,507,130	111,507,130	111,080,517
May 2022	111,507,130	111,507,130	111,074,209
June 2022	111,507,130	111,507,130	111,058,696
July 2022	111,507,130	111,507,130	111,067,232
August 2022	111,507,130	111,507,130	111,068,833
September 2022	111,507,130	111,507,130	111,050,693
October 2022	111,507,130	111,507,130	111,017,003
November 2022	111,507,130	111,507,130	110,970,670

Month	Total number of outstanding shares	Theoretical voting rights	Exercisable voting rights (minus treasury shares)
January 2021	78,317,810	78,317,810	78,043,444
February 2021	78,317,810	78,317,810	78,068,890
March 2021	78,317,810	78,317,810	78,073,890
April 2021	91,994,935	91,994,935	91,746,015
May 2021	91,994,935	91,994,935	91,711,015
June 2021	91,994,935	91,994,935	91,701,015
July 2021	91,994,935	91,994,935	91,679,295
August 2021	91,994,935	91,994,935	91,679,295
September 2021	91,994,935	91,994,935	91,655,221
October 2021	91,994,935	91,994,935	91,618,366
November 2021	91,994,935	91,994,935	91,562,673

Month	Total number of outstanding shares	Theoretical voting rights	Exercisable voting rights (minus treasury shares)
January 2020	63,498,801	63,498,801	63,164,831
February 2020	64,698,801	64,698,801	64,334,915
March 2020	65,798,801	65,798,801	65,419,241
April 2020	67,762,234	67,762,234	67,391,300
May 2020	68,181,359	68,181,359	68,026,409
June 2020	78,317,810	78,317,810	78,117,816
July 2020	78,317,810	78,317,810	78,072,666
August 2020	78,317,810	78,317,810	78,092,666
September 2020	78,317,810	78,317,810	78,042,666
October 2020	78,317,810	78,317,810	78,012,771
November 2020	78,317,810	78,317,810	78,094,959
December 2020	78,317,810	78,317,810	78,045,372

Month	Total number of outstanding shares	Theoretical voting rights	Exercisable voting rights (minus treasury shares)
January 2019	54,076,375	54,076,375	53,957,589
February 2019	54,676,375	54,676,375	54,540,131
March 2019	55,176,171	55,176,171	54,993,329
April 2019	55,559,464	55,559,464	55,389,278
May 2019	55,614,722	55,614,722	55,435,637
June 2019	55,814,722	55,814,722	55,603,864
July 2019	56,705,426	56,705,426	56,478,873
August 2019	57,405,351	57,405,351	57,104,990
September 2019	58,355,351	58,355,351	58,022,045
October 2019	59,255,351	59,255,351	58,898,166
November 2019	60,355,351	60,355,351	60,005,300
December 2019	61,317,851	61,317,851	60,976,782

Month	Total number of outstanding shares	Theoretical voting rights	Exercisable voting rights (minus treasury shares)
January 2018	50,695,653	50,695,653	50,647,532
February 2018	50,695,653	50,695,653	50,621,624
March 2018	50,695,653	50,695,653	50,598,574
April 2018	50,695,653	50,695,653	50,603,445
May 2018	50,695,653	50,695,653	50,601,485
June 2018	50,735,653	50,735,653	50,647,077
July 2018	51,596,515	51,596,515	51,524,588
August 2018	52,460,497	52,460,497	52,375,831
September 2018	53,076,375	53,076,375	52,997,691
October 2018	53,176,375	53,176,375	53,103,306
November 2018	53,376,375	53,376,375	53,288,763
December 2018	53,376,375	53,376,375	53,265,280

Month	Total number of outstanding shares	Theoretical voting rights	Exercisable voting rights (minus treasury shares)
January 2017	47,043,404	47,043,404	47,026,286
February 2017	47,043,404	47,043,404	47,003,914
March 2017	47,043,404	47,043,404	47,015,589
April 2017	47,043,404	47,043,404	47,018,265
May 2017	47,043,404	47,043,404	47,022,037
June 2017	50,572,815	50,572,815	50,558,986
July 2017	50,689,965	50,689,965	50,668,595
August 2017	50,695,653	50,695,653	50,679,798
September 2017	50,695,653	50,695,653	50,653,592
October 2017	50,695,653	50,695,653	50,613,993
November 2017	50,695,653	50,695,653	50,613,993
December 2017	50,695,653	50,695,653	50,612,993

Month	Total number of outstanding shares	Theoretical voting rights	Exercisable voting rights (minus treasury shares)
January 2016	40,552,083	40,552,083	40,537,438
February 2016	40,552,083	40,552,083	40,537,881
March 2016	40,552,083	40,552,083	40,521,970
April 2016	41,470,860	41,470,860	41,455,537
May 2016	41,470,860	41,470,860	41,428,223
June 2016	41,470,860	41,470,860	41,437,953
July 2016	41,470,860	41,470,860	41,450,839
August 2016	41,470,860	41,470,860	41,439,131
September 2016	41,470,860	41,470,860	41,417,902
October 2016	46,905,643	46,905,643	46,871,481
November 2016	46,905,643	46,905,643	46,864,125
December 2016	47,043,404	47,043,404	47,019,604